China Digest: Sequoia backs Neurophth; TransThera bags over $50m
February 9, 2021
Wuhan Neurophth Biological Technology has secured 400 million yuan ($62 million) in a Series B round of financing jointly led by Guofang FOF and InnoVision Capital, while Nanjing TransThera Biosciences has garnered over $50 million led by Co-Stone Asset Management.
Sequoia backs gene therapy company Neurophth
Chinese ophthalmic gene therapy technology company Wuhan Neurophth Biological Technology Co., Ltd has secured 400 million yuan ($62 million) in a Series B round of financing, according to a company statement on Tuesday.
The fresh round was co-led by Shanghai International Group’s Guofang FOF and Greater China-focused PE firm InnoVision Capital, while new investors including Oriza Holdings, Grand Mount Capital, and Yuanfeng Capital joined the round.